Browsing by title
Now showing items 448-467 of 4595
-
Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?
(AMER ASSOC CANCER RESEARCH, 2016-05-01)Tolerability of molecularly targeted agents (MTA) used in cancer therapeutics is determined in phase I trials. We reviewed the reported incidence of toxicity in phase III trials at doses and schedules recommended by phase ... -
Are There Specific Cancer Stem Cell Markers?
(AMER ASSOC CANCER RESEARCH, 2023-01-18)The cancer stem cell (CSC) model states that heterogeneous tumor cell populations are organized in a hierarchical manner, with a small population of CSCs at the apex. These CSCs are capable of self-renewal and giving rise ... -
ARHGEF9 regulates melanoma morphogenesis in environments with diverse geometry and elasticity by promoting filopodial-driven adhesion.
(CELL PRESS, 2022-08-19)Rho GTP Exchange Factors (RhoGEFs) and Rho GTPase Activating Proteins (RhoGAPs) are large families of molecules that regulate shape determination in all eukaryotes. In pathologies such as melanoma, RhoGEF and RhoGAP activity ... -
ARID1A influences HDAC1/BRD4 activity, intrinsic proliferative capacity and breast cancer treatment response.
(NATURE PORTFOLIO, 2020-02-01)Using genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screens to understand endocrine drug resistance, we discovered ARID1A and other SWI/SNF complex components as the factors most critically ... -
Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy.
(DOVE MEDICAL PRESS LTD, 2021-01-01)Chimeric antigen receptor (CAR) T-cell therapy engineers T-cells to express a synthetic receptor which redirects effector function to the tumor, to improve efficacy and reduce toxicities associated with conventional ... -
Arresting metastasis within the microcirculation.
(SPRINGER, 2021-07-09)The behaviour of circulating tumour cells in the microcirculation remains poorly understood. Growing evidence suggests that biomechanical adaptations and interactions with blood components, i.e. immune cells and platelets ... -
ART DECO (CRUK/10/018): dose escalated vs standard dose IMRT in locally advanced head and neck cancer
(ELSEVIER IRELAND LTD, 2017-03-01) -
Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology.
(ELSEVIER, 2021-02-06)The field of immuno-oncology has expanded rapidly over the past decade, but key questions remain. How does tumour-immune interaction regulate disease progression? How can we prospectively identify patients who will benefit ... -
Asparagine bioavailability governs metastasis in a model of breast cancer.
(NATURE PORTFOLIO, 2018-02-15)Using a functional model of breast cancer heterogeneity, we previously showed that clonal sub-populations proficient at generating circulating tumour cells were not all equally capable of forming metastases at secondary ... -
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
<h4>Background</h4>Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients admitted to hospital with ... -
Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-analysis.
(AMER ASSOC CANCER RESEARCH, 2019-03-01)BACKGROUND: There have been few studies of sufficient size to address the relationship between glioma risk and the use of aspirin or NSAIDs, and results have been conflicting. The purpose of this study was to examine the ... -
Assessing Bladder Radiotherapy Response With Quantitative Diffusion-Weighted Magnetic Resonance Imaging Analysis.
(ELSEVIER SCIENCE LONDON, 2022-05-06)AIMS: Radiotherapy with radiosensitisation offers opportunity for cure with organ preservation in muscle-invasive bladder cancer (MIBC). Treatment response assessment and follow-up are reliant on regular endoscopic evaluation ... -
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis.
(AMER ASSOC CANCER RESEARCH, 2022-03-15)PURPOSE: Cerebrospinal fluid (CSF) cytology is the gold standard diagnostic test for breast cancer leptomeningeal metastasis (BCLM), but has impaired sensitivity, often necessitating repeated lumbar puncture to confirm or ... -
Assessing HER2 Amplification in Plasma cfDNA.
(HUMANA PRESS INC, 2018-05-02)Digital PCR (dPCR) is a highly accurate method to determine DNA concentration. In dPCR, DNA is portioned into many discrete single entities, and these are analyzed individually for the presence or absence of a target ... -
Assessing histone demethylase inhibitors in cells: lessons learned.
(BIOMED CENTRAL LTD, 2017-03-01)BACKGROUND: Histone lysine demethylases (KDMs) are of interest as drug targets due to their regulatory roles in chromatin organization and their tight associations with diseases including cancer and mental disorders. The ... -
Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study.
(2018-03)When patients randomised to the control group of a randomised controlled trial are allowed to switch onto the experimental treatment, intention-to-treat analyses of the treatment effect are confounded because the separation ... -
Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.
(NATURE PUBLISHING GROUP, 2017-06-16) -
Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases.
(ELIFE SCIENCES PUBLICATIONS LTD, 2016-12-09)Mediator-associated kinases CDK8/19 are context-dependent drivers or suppressors of tumorigenesis. Their inhibition is predicted to have pleiotropic effects, but it is unclear whether this will impact on the clinical utility ... -
Assessing the reporting quality of early phase dose-finding trial protocols: a methodological review.
(ELSEVIER, 2023-06-01)BACKGROUND: The paradigm of early phase dose-finding trials has evolved in recent years. Innovative dose-finding designs and protocols which combine phases I and II are becoming more popular in health research. However, ...